PRAME/EZH2-mediated regulation of TRAIL: A new target for cancer therapy

Current Molecular Medicine

Volumn 13, Issue 2, 2013, Pages 296-304

  de Carvalho, Daniel D ^a   Mello, B P ^b   Pereira, W O ^b   Amarante Mendes, G P ^b,c  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c Instituto de Investigac ão em Imunologia Instituto Nacional de Ciência e Tecnologia INCT   (Brazil)

Author keywords

Apoptosis; Cancer; Ezh2; Polycomb genes; Prame; Trail

Indexed keywords

EID: 84874923971     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313020006     Document Type: Article

References (102)

1. Wiley SR, Schooley K, Smolak PJ, et al Identification and characterization of a new member of the TNF family that induces apoptosis.Immunity 1995; 6: 673-682.
2. Pitti RM, Marsters SA, Ruppert S, Donahue CJ, Moore A, Ashkenazi A.Induction of apoptosis by Apo-2 ligand, a new member of the tumor necrosis factor cytokine family.J Biol Chem 1996; 22: 12687-12690.
3. Sedger LM, Shows DM, Blanton RA, et al IFN-gamma mediates a novel antiviral activity through dynamic modulation of TRAIL and TRAIL receptor expression.J Immunol 1999; 2: 920-926.
4. Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T, Debatin KM.Inhibition of nuclear factor kappaB activation attenuates apoptosis resistance in lymphoid cells.Blood 1998; 12: 4624- 4631.
5. Cummins N, Badley A.The TRAIL to viral pathogenesis: the good, the bad and the ugly.Curr Mol Med 2009; 4: 495-505.
6. Janssen EM, Droin NM, Lemmens EE, et al CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death.Nature 2005; 7029: 88-93.
7. Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B.Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells.J Exp Med 1998; 12: 2375-2380.
8. Johnsen AC, Haux J, Steinkjer B, et al Regulation of APO-2 ligand/trail expression in NK cells-involvement in NK cellmediated cytotoxicity.Cytokine 1999; 9: 664-672.
9. Robertson NM, Zangrilli JG, Steplewski A, et al Differential expression of TRAIL and TRAIL receptors in allergic asthmatics following segmental antigen challenge: evidence for a role of TRAIL in eosinophil survival.J Immunol 2002; 10: 5986-5996.
10. Song K, Chen Y, Goke R, et al Tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression.J Exp Med 2000; 7: 1095-1104.
11. Amarante-Mendes GP, Green DR.The regulation of apoptotic cell death.Braz J Med Biol Res 1999; 9: 1053-1061.
12. Gonzalvez F, Ashkenazi A.New insights into apoptosis signaling by Apo2L/TRAIL.Oncogene 2010; 34: 4752-4765.
13. Degli-Esposti MA, Dougall WC, Smolak PJ, Waugh JY, Smith CA, Goodwin RG.The novel receptor TRAIL-R4 induces NF-kappaB and protects against TRAIL-mediated apoptosis, yet retains an incomplete death domain.Immunity 1997; 6: 813-820.
14. MacFarlane M, Ahmad M, Srinivasula SM, Fernandes- Alnemri T, Cohen GM, Alnemri ES.Identification and molecular cloning of two novel receptors for the cytotoxic ligand TRAIL.J Biol Chem 1997; 41: 25417-25420.
15. Marsters SA, Sheridan JP, Pitti RM, et al A novel receptor for Apo2L/TRAIL contains a truncated death domain.Curr Biol 1997; 12: 1003-1006.
16. Sheridan JP, Marsters SA, Pitti RM, et al Control of TRAILinduced apoptosis by a family of signaling and decoy receptors.Science 1997; 5327: 818-821.
17. Schneider P, Bodmer JL, Thome M, Hofmann K, Holler N, Tschopp J.Characterization of two receptors for TRAIL.FEBS Lett 1997; 3: 329-334.
18. Pan G, O'Rourke K, Chinnaiyan AM, et al The receptor for the cytotoxic ligand TRAIL.Science 1997; 5309: 111-113.
19. Emery JG, McDonnell P, Burke MB, et al Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL.J Biol Chem 1998; 23: 14363-14367.
20. Yamaguchi K, Kinosaki M, Goto M, et al Characterization of structural domains of human osteoclastogenesis inhibitory factor.J Biol Chem 1998; 9: 5117-5123.
21. Suliman A, Lam A, Datta R, Srivastava RK.Intracellular mechanisms of TRAIL: apoptosis through mitochondrialdependent and -independent pathways.Oncogene 2001; 17: 2122-2133.
22. Falschlehner C, Schaefer U, Walczak H.Following TRAIL's path in the immune system.Immunology 2009; 2: 145-154.
23. Chaudhary PM, Eby M, Jasmin A, Bookwalter A, Murray J, Hood L.Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-kappaB pathway.Immunity 1997; 6: 821-830.
24. Bodmer JL, Holler N, Reynard S, et al TRAIL receptor-2 signals apoptosis through FADD and caspase-8.Nat Cell Biol 2000; 4: 241-243.
25. Thomas LR, Henson A, Reed JC, Salsbury FR, Thorburn A.Direct binding of Fas-associated death domain (FADD) to the tumor necrosis factor-related apoptosis-inducing ligand receptor DR5 is regulated by the death effector domain of FADD.J Biol Chem 2004; 31: 32780-32785.
26. Ricci MS, Jin Z, Dews M, et al Direct repression of FLIP expression by c-myc is a major determinant of TRAIL sensitivity.Mol Cell Biol 2004; 19: 8541-8555.
27. Ashkenazi A, Herbst RS.To kill a tumor cell: the potential of proapoptotic receptor agonists.J Clin Invest 2008; 6: 1979- 1990.
28. Corazza N, Kassahn D, Jakob S, Badmann A, Brunner T.TRAIL-induced apoptosis: between tumor therapy and immunopathology.Ann N Y Acad Sci 2009; 1171: 50-58.
29. Ozören N, El-Deiry WS.Defining characteristics of Types I and II apoptotic cells in response to TRAIL.Neoplasia 2002; 6: 551-557.
30. Barnhart BC, Alappat EC, Peter ME.The CD95 type I/type II model.Semin Immunol 2003; 3: 185-193.
31. Luo X, Budihardjo I, Zou H, Slaughter C, Wang X.Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors.Cell 1998; 4: 481-490.
32. Li H, Zhu H, Xu CJ, Yuan J.Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis.Cell 1998; 4: 491-501.
33. Kandasamy K, Srinivasula SM, Alnemri ES, et al Involvement of proapoptotic molecules Bax and Bak in tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)- induced mitochondrial disruption and apoptosis: differential regulation of cytochrome c and Smac/DIABLO release.Cancer Res 2003; 7: 1712-1721.
34. Verhagen AM, Ekert PG, Pakusch M, et al Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins.Cell 2000; 1: 43- 53.
35. Du C, Fang M, Li Y, Li L, Wang X.Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition.Cell 2000; 1: 33-42.
36. Gray CW, Ward RV, Karran E, et al Characterization of human HtrA2, a novel serine protease involved in the mammalian cellular stress response.Eur J Biochem 2000; 18: 5699-5710.
37. Savopoulos JW, Carter PS, Turconi S, et al Expression, purification, and functional analysis of the human serine protease HtrA2.Protein Expr Purif 2000; 2: 227-234.
38. Ruiz-Carrillo A, Renaud J.Endonuclease G: a (dG)n X (dC)n-specific DNase from higher eukaryotes.EMBO J 1987; 2: 401-407.
39. Cote J, Renaud J, Ruiz-Carrillo A.Recognition of (dG)n.(dC)n sequences by endonuclease G.Characterization of the calf thymus nuclease.J Biol Chem 1989; 6: 3301-3310.
40. Susin SA, Zamzami N, Castedo M, et al Bcl-2 inhibits the mitochondrial release of an apoptogenic protease.J Exp Med 1996; 4: 1331-1341.
41. Jost PJ, Grabow S, Gray D, et al XIAP discriminates between type I and type II FAS-induced apoptosis.Nature 2009; 7258: 1035-1039.
42. LeBlanc H, Lawrence D, Varfolomeev E, et al Tumor-cell resistance to death receptor--induced apoptosis through mutational inactivation of the proapoptotic Bcl-2 homolog Bax.Nat Med 2002; 3: 274-281.
43. Secchiero P, Gonelli A, Carnevale E, et al TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways.Circulation 2003; 17: 2250-2256.
44. Falschlehner C, Emmerich CH, Gerlach B, Walczak H.TRAIL signalling: decisions between life and death.Int J Biochem Cell Biol 2007; 7-8: 1462-75.
45. Lin Y, Devin A, Cook A, et al The death domain kinase RIP is essential for TRAIL (Apo2L)-induced activation of IkappaB kinase and c-Jun N-terminal kinase.Mol Cell Biol 2000; 18: 6638-6645.
46. Varfolomeev E, Maecker H, Sharp D, et al Molecular determinants of kinase pathway activation by Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand.J Biol Chem 2005; 49: 40599-40608.
47. Jin Z, El-Deiry WS.Distinct signaling pathways in TRAILversus tumor necrosis factor-induced apoptosis.Mol Cell Biol 2006; 21: 8136-8148.
48. Belyanskaya LL, Ziogas A, Hopkins-Donaldson S, et al TRAIL-induced survival and proliferation of SCLC cells is mediated by ERK and dependent on TRAIL-R2/DR5 expression in the absence of caspase-8.Lung Cancer 2008; 3: 355-365.
49. Secchier li o P, Melloni E, Corallini F, et al Tumor necrosis factor-related apoptosis-inducing gand promotes migration of human bone marrow multipotent stromal cells.Stem Cells 2008; 11: 2955-2963.
50. Chen L, Park SM, Tumanov AV, et al CD95 promotes tumour growth.Nature 2010; 7297: 492-496.
51. Peter ME, Budd RC, Desbarats J, et al The CD95 receptor: apoptosis revisited.Cell 2007; 3: 447-450.
52. Walczak H, Miller RE, Ariail K, et al Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.Nat Med 1999; 2: 157-163.
53. Cretney E, Takeda K, Yagita H, Glaccum M, Peschon JJ, Smyth MJ.Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice.J Immunol 2002; 3: 1356-1361.
54. Sedger LM, Glaccum MB, Schuh JC, et al Characterization of the in vivo function of TNF-alpha-related apoptosisinducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L genedeficient mice.Eur J Immunol 2002; 8: 2246-2254.
55. Clarke N, Jimenez-Lara AM, Voltz E, Gronemeyer H.Tumor suppressor IRF-1 mediates retinoid and interferon anticancer signaling to death ligand TRAIL.EMBO J 2004; 15: 3051-3060.
56. Kayagaki N, Yamaguchi N, Nakayama M, Eto H, Okumura K, Yagita H.Type I interferons (IFNs) regulate tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) expression on human T cells: A novel mechanism for the antitumor effects of type I IFNs.J Exp Med 1999; 9: 1451-1460.
57. Griffith TS, Wiley SR, Kubin MZ, Sedger LM, Maliszewski CR, Fanger NA.Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL.J Exp Med 1999; 8: 1343-1354.
58. Fanger NA, Maliszewski CR, Schooley K, Griffith TS.Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL).J Exp Med 1999; 8: 1155-1164.
59. Kayagaki N, Yamaguchi N, Nakayama M, et al Expression and function of TNF-related apoptosis-inducing ligand on murine activated NK cells.J Immunol 1999; 4: 1906-1913.
60. Daniels RA, Turley H, Kimberley FC, et al Expression of TRAIL and TRAIL receptors in normal and malignant tissues.Cell Res 2005; 6: 430-438.
61. De Carvalho DD, Binato R, Pereira WO, et al BCR-ABLmediated upregulation of PRAME is responsible for knocking down TRAIL in CML patients.Oncogene 2011; 2: 223-233.
62. Ghaffari S, Jagani Z, Kitidis C, Lodish HF, Khosravi-Far R.Cytokines and BCR-ABL mediate suppression of TRAILinduced apoptosis through inhibition of forkhead FOXO3a transcription factor.Proc Natl Acad Sci USA 2003; 11: 6523-6528.
63. Huang H, Tindall DJ.Dynamic FoxO transcription factors.J Cell Sci 2007; 120(Pt 15): 2479-2487.
64. Epping MT, Bernards R.A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer.Cancer Res 2006; 22: 10639-10642.
65. Ikeda H, Lethé B, Lehmann F, et al Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor.Immunity 1997; 2: 199-208.
66. Epping MT, Wang L, Edel MJ, Carlée L, Hernandez M, Bernards R.The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling.Cell 2005; 6: 835-847.
67. Altucci L, Rossin A, Raffelsberger W, Reitmair A, Chomienne C, Gronemeyer H.Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumorselective death ligand TRAIL.Nat Med 2001; 6: 680-686.
68. Kirmizis A, Bartley SM, Kuzmichev A, et al Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27.Genes Dev 2004; 13: 1592-1605.
69. Cao R, Wang L, Wang H, et al Role of histone H3 lysine 27 methylation in Polycomb-group silencing.Science 2002; 5595: 1039-1043.
70. Lund AH, van Lohuizen M.Polycomb complexes and silencing mechanisms.Curr Opin Cell Biol 2004; 3: 239-46.
71. Kelly TK, De Carvalho DD, Jones PA.Epigenetic modifications as therapeutic targets.Nat Biotechnol 2010; 10: 1069-1078.
72. Tan J, Yang X, Zhuang L, et al Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells.Genes Dev 2007; 9: 1050-1063.
73. Gal-Yam EN, Egger G, Iniguez L, et al Frequent switching of Polycomb repressive marks and DNA hypermethylation in the PC3 prostate cancer cell line.Proc Natl Acad Sci USA 2008; 35: 12979-12984.
74. Shi J, Zheng D, Man K, Fan ST, Xu R.TRAIL: a potential agent for cancer therapy.Curr Mol Med 2003; 8: 727-736.
75. Newsom-Davis T, Prieske S, Walczak H.Is TRAIL the holy grail of cancer therapy? Apoptosis 2009; 4: 607-623.
76. Carlo-Stella C, Lavazza C, Locatelli A, Viganò L, Gianni AM, Gianni L.Targeting TRAIL agonistic receptors for cancer therapy.Clin Cancer Res 2007; 8: 2313-2317.
77. Lee J, Hampl M, Albert P, Fine HA.Antitumor activity and prolonged expression from a TRAIL-expressing adenoviral vector.Neoplasia 2002; 4: 312-323.
78. Holoch PA, Griffith TS.TNF-related apoptosis-inducing ligand (TRAIL): a new path to anti-cancer therapies.Eur J Pharmacol 2009; 1-3: 63-72.
79. Griffith TS, Anderson RD, Davidson BL, Williams RD, Ratliff TL.Adenoviral-mediated transfer of the TNF-related apoptosis-inducing ligand/Apo-2 ligand gene induces tumor cell apoptosis.J Immunol 2000; 5: 2886-2894.
80. Pesonen S, Kangasniemi L, Hemminki A.Oncolytic adenoviruses for the treatment of human cancer: focus on translational and clinical data.Mol Pharm 2011; 1: 12-28.
81. Collins SA, Guinn BA, Harrison PT, Scallan MF, O'Sullivan GC, Tangney M.Viral vectors in cancer immunotherapy: which vector for which strategy? Curr Gene Ther 2008; 2: 66-78.
82. Kaplan JM.Adenovirus-based cancer gene therapy.Curr Gene Ther 2005; 6: 595-605.
83. Yin B.PRAME: From diagnostic marker and tumor antigen to promising target of RNAi therapy in leukemic cells.Leuk Res 2011; 9: 1159-11160.
84. Zhou J, Bi C, Cheong LL, et al The histone methyltransferase inhibitor DZNep upregulates TXNIP, increases ROS production, and targets leukemia cells in AML.Blood 2011; 10: 2830-2839.
85. De Carvalho DD, Sharma S, You JS, et al DNA methylation screening identifies driver epigenetic events of cancer cell survival.Cancer Cell 2012; 5: 655-667.
86. Huang Y, Stewart TM, Wu Y, et al Novel oligoamine analogues inhibit lysine-specific demethylase 1 and induce reexpression of epigenetically silenced genes.Clin Cancer Res 2009; 23: 7217-7228.
87. Miranda TB, Cortez CC, Yoo CB, et al DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation.Mol Cancer Ther 2009; 6: 1579-1588.
88. Quintarelli C, Dotti G, Hasan ST, et al High-avidity cytotoxic T lymphocytes specific for a new PRAME-derived peptide can target leukemic and leukemic-precursor cells.Blood 2011; 12: 3353-3362.
89. Insinga A, Monestiroli S, Ronzoni S, et al Inhibitors of histone deacetylases induce tumor-selective apoptosis through activation of the death receptor pathway.Nat Med 2005; 1: 71-76.
90. Nebbioso A, Clarke N, Voltz E, et al Tumor-selective action of HDAC inhibitors involves TRAIL induction in acute myeloid leukemia cells.Nat Med 2005; 1: 77-84.
91. Ozoren N, El-Deiry WS.Cell surface Death Receptor signaling in normal and cancer cells.Semin Cancer Biol 2003; 2: 135-147.
92. Grimm M, Kim M, Rosenwald A, et al Tumour-mediated TRAIL-Receptor expression indicates effective apoptotic depletion of infiltrating CD8+ immune cells in clinical colorectal cancer.Eur J Cancer 2010; 12: 2314-2323.
93. Nimmanapalli R, Porosnicu M, Nguyen D, et al Cotreatment with STI-571 enhances tumor necrosis factor alpha-related apoptosis-inducing ligand (TRAIL or apo-2L)-induced apoptosis of Bcr-Abl-positive human acute leukemia cells.Clin Cancer Res 2001; 2: 350-735.
94. Pavet V, Portal MM, Moulin JC, Herbrecht R, Gronemeyer H.Towards novel paradigms for cancer therapy.Oncogene 2011; 1: 1-20.
95. Sgorbissa A, Tomasella A, Potu H, Manini I, Brancolini C.Type I IFNs signaling and apoptosis resistance in glioblastoma cells.Apoptosis 2011; 12: 1229-1244.
96. Lee J, Shin JS, Park JY, et al p38 mitogen-activated protein kinase modulates expression of tumor necrosis factor-related apoptosis-inducing ligand induced by interferon-gamma in fetal brain astrocytes.J Neurosci Res 2003; 6: 884-890.
97. Wang Q, Zhou Y, Weiss HL, Chow CW, Evers BM.NFATc1 regulation of TRAIL expression in human intestinal cells.PLoS One 2011; 5: e19882.
98. Wilson MK, McWhirter SM, Amin RH, Huang D, Schlissel MS.Abelson virus transformation prevents TRAIL expression by inhibiting FoxO3a and NF-kappaB.Mol Cells 2010; 4: 333-431.
99. Robbins MA, Maksumova L, Pocock E, Chantler JK.Nuclear factor-kappaB translocation mediates double-stranded ribonucleic acid-induced NIT-1 beta-cell apoptosis and upregulates caspase-12 and tumor necrosis factor receptorassociated ligand (TRAIL).Endocrinology 2003; 10: 4616-4625.
100. Cho YS, Challa S, Clancy L, Chan FK.Lipopolysaccharideinduced expression of TRAIL promotes dendritic cell differentiation.Immunology 2010; 4: 504-515.
101. Ellison-Zelski SJ, Alarid ET.Maximum growth and survival of estrogen receptor-alpha positive breast cancer cells requires the Sin3A transcriptional repressor.Mol Cancer 2010; 9: 263.
102. Barker BR, Gladstone MN, Gillard GO, Panas MW, Letvin NL.Critical role for IL-21 in both primary and memory antiviral CD8+ T-cell responses.Eur J Immunol 2010; 11: 3085-3096.